To date, studies comparing diagnostic accuracy between molecular imaging methods, considers SSTR-PET to be the first line diagnostic method for pheochromocytoma/paraganglioma patients carrying SDHx related mutations and most often for paraganglioma originating in the head and neck region, and [18F]F-DOPA-PET to be the first line diagnostic method for pheochromocytoma/paraganglioma patients carrying other mutations (such as MEN2A) and for tumours of adrenal origin including sporadic cases (Nölting et al. 2022; Taïeb et al. 2019; Jha et al. 2022; Archier et al. 2016; Janssen et al. 2016a, b). Here, RET is linked to paraganglioma.